September 25, 2024Open Access

Tislelizumab plus chemotherapy versus chemotherapy alone as first-line treatment for advanced squamous non-small-cell lung cancer: final analysis of the randomized, phase III RATIONALE-307 trial

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

The RATIONALE-307 final analysis demonstrated superior clinical benefit with addition of tislelizumab to chemotherapy, and a manageable safety profile, as first-line treatment of advanced sq-NSCLC.

Me gusta

Guardar

Ver artículo completo

Cite This Study

Wang et al. (Wed,) studied this question.

synapsesocial.com/papers/69dcca810de68e8319e5382d https://doi.org/https://doi.org/10.1016/j.esmoop.2024.103727

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1LBA3 Nivolumab (NIVO) + platinum-doublet chemotherapy (chemo) vs chemo as first-line (1L) treatment (tx) for advanced non-small cell lung cancer (aNSCLC): CheckMate 227 - part 2 final analysis2019 · 48 citations
2Survival Disparities in Non–Small Cell Lung Cancer by Race, Ethnicity, and Socioeconomic Status2014 · 117 citations
3The binding of an anti-PD-1 antibody to FcγRΙ has a profound impact on its biological functions2018 · 289 citations
4Abstract 2383: The molecular binding mechanism of tislelizumab, an investigational anti-PD-1 antibody, is differentiated from pembrolizumab and nivolumab2019 · 17 citations
5Updated Overall Survival Analysis From IMpower110: Atezolizumab Versus Platinum-Based Chemotherapy in Treatment-Naive Programmed Death-Ligand 1–Selected NSCLC2021 · 202 citations

Me gusta

Guardar

Ver artículo completo